Aug 182026 Biomarkers of nivolumab benefit in resectable nonsmall cell lung cancer Potential predictive biomarkers of perioperative nivolumab therapy benefit in non-small cell lung cancer are identified from evaluable participants in the CheckMate 77T trial.
